|
|
Vaccine Detail
|
TVI-Brain-1 |
| Vaccine Information |
- Vaccine Name: TVI-Brain-1
- Target Pathogen: Cancer
- Target Disease: Cancer
- Type: whole cell cancer vaccine
- Status: Clinical trial
- Host Species for Licensed Use: None
- Antigen: cancer neoantigens (NCIT_C199632)
- Immunization Route: Other
- Description: To make the vaccine, the patient's cancer will be surgically removed to provide cells for the vaccine, then the patient will be vaccinated twice with those cells and GM-CSF. After, the patient's blood will be filtered for white cells which will then be cultured and stimulated to reach a higher (killer) activity level. Next, the activated white blood cells will be infused into the patient's bloodstream so that they will be able to attack the cancer. Lastly, the entire process starting with vaccination will be repeated, for a total of two rounds of therapy. (NCT01081223) The autologous vaccine-enhanced ex vivo activated cancer neoantigens-specific T-cells TVI-Brain-1 recognize and bind to tumor cells expressing the cancer neoantigens, resulting in a cytotoxic T-lymphocyte (CTL)-mediated immune response against the patient's tumor cells. (NCIT_C199632)
|
| Host Response |
|
|
| References |
NCIT_C199632: Autologous Vaccine-enhanced Ex Vivo Activated Cancer Neoantigens-specific T-cells TVI-Brain-1 [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C199632]
NCT01081223: Phase I/II Study To Test The Safety and Efficacy of TVI-Brain-1 As A Treatment For Recurrent Grade IV Glioma [https://clinicaltrials.gov/study/NCT01081223]
|
|
